INS and Obesity: It has been shown to enhance insulin sensitivity in individuals with prediabetes, type 2 diabetes mellitus, obesity, polycystic ovary syndrome, and non-alcoholic hepatic steatosis by increasing peripheral glucose utilization, augmenting insulin receptor tyrosine kinase activity, promoting glycogen synthesis, and enhancing the recruitment and activity of GLUT4 [184].